Biparametric MRI, which omits dynamic contrast-enhanced sequences, similarly detected clinically significant prostate cancer to multiparametric MRI. Biparametric MRI was also noninferior to ...

Microultrasonography-guided prostate biopsy proved noninferior to MRI/conventional ultrasound-fusion (MRI/US-fusion) imaging for detecting clinically significant cancer, a large randomized trial ...

Omitting biopsy in patients with a negative prostate MRI more than halves the diagnoses of clinically insignificant prostate cancer. Detection of clinically insignificant ISUP grade group 1 prostate ...

Data on the efficacy and safety of screening for prostate cancer with magnetic resonance imaging (MRI) are needed from studies of follow-up screening. In a population-based trial that started in 2015, ...

Prostate cancer is the second-leading cause of death among American men, killing one in 44. In the United States, 3.3 million men are survivors of prostate cancer, and the risk for developing the ...

Among patients with prostate cancer who received MRI-guided stereotactic body radiation therapy (SABR), more than 80% demonstrated “classic” neurovascular bundle patterns and over 96% showed more than ...

The study protocol was approved by the institutional review board of Hokkaido University Hospital, and patient consent was not deemed necessary because data were obtained from medical charts and ...

AI-driven MRI analysis offers new insights into prostate cancer prognosis, accurately predicting metastasis risk and treatment outcomes for improved patient care. Study: AI-derived Tumor Volume from ...

Omitting systematic biopsy in men with elevated prostate-specific antigen (PSA) levels and negative MRI results, and performing only targeted biopsy of MRI-positive lesions, eliminated more than half ...